Alenin, V. V. et al. published new experimental results with the assistance of cas: 54147-04-5

Ethyl 5-amino-1-methyl-1H-imidazole-4-carboxylate (cas: 54147-04-5 Application of 54147-04-5) is a synthetic retinoid that has been shown to be effective in the treatment of psoriasis. It inhibits the activation of histone lysine residues and increases the terminal half life of endogenous synthesis.

Application of 54147-04-5《Reductive methylation of N1-substituted 4-ethoxycarbonyl-5-imidazoles》 was published in 1980. The authors were Alenin, V. V.;Domkin, V. D., and the article was included in《Zhurnal Obshchei Khimii》. The author mentioned the following in the article:

Reductive methylation of I (R1 = Me, R2 = H, R3 = Et) by CH2O and NaBH4 gave I (R1 = R2 = Me, R3 = Et) which was hydrolyzed by base to give I (R1 = R2 = Me, R3 = H). Analogously obtained was I (R1 = 2,3-O-isopropylidene-β-D-ribofuranosyl, R2 = Me, R3 = Et) which was phosphorylated and deblocked to give I (R1 = 5-O-phospho-β-D-ribofuranosyl, R2 = Me, R3 = H). And Ethyl 5-amino-1-methyl-1H-imidazole-4-carboxylate (cas: 54147-04-5) was used in the research process.

Ethyl 5-amino-1-methyl-1H-imidazole-4-carboxylate (cas: 54147-04-5 Application of 54147-04-5) is a synthetic retinoid that has been shown to be effective in the treatment of psoriasis. It inhibits the activation of histone lysine residues and increases the terminal half life of endogenous synthesis.

Reference:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem